The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

Eli Lilly reassures investors about strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro. Despite supply chain issues and lower-than-expected sales, the company expects ...

Zepbound (tirzepatide) is a prescription injection that comes as a single-dose pen or single-dose vial. If your doctor prescribes Zepbound to you and you need to travel, there are certain things ...

With more patients using LillyDirect, the uptake of single-uses Zepbound vials increased. We had no wholesaler backorders as we closed 2024, and wholesalers have been fulfilling orders from ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.